A report issued by the Attorney General for Vermont, USA, William Sorrell (Democrat), has revealed that 78 pharmaceutical firms spent in excess of $2.9 million in 2008 on marketing to physicians, clinics and universities in the northeastern state. The Vermont administration is campaigning to end drugmakers' ability to prevent publication of the recipients names where a "trade secret" is alleged by the sponsor.
The leading companies involved were USA-based Eli Lilly, Forest Pharmaceuticals, Merck & Co and Pfizer, as well as Swiss drug major Novartis, according to the report. Over 80% of recorded marketing expenditure was categorized as "trade secrets."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze